Therapeutic peptides

Trends in Biotechnology

Volumn 21, Issue 12, 2003, Pages 556-562

  Lien, Samantha ^a   Lowman, Henry B ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; DRUG THERAPY; MEDICAL APPLICATIONS; TUMORS;

SYNTHETIC PEPTIDE LIBRARIES;

PROTEINS;

ABARELIX; APAN; CALCITONIN; CANCER VACCINE; ENFUVIRTIDE; EXENDIN 4; EXUBRA; IABETA5P; IB 367; INSULIN; ISEGANAN; LEUPRORELIN; ONCOGENE NEU VACCINE; ORATONIN; PRAMLINTIDE; SYNTHETIC PEPTIDE; T 1249; UNCLASSIFIED DRUG;

PEPTIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AEROSOL; ALZHEIMER DISEASE; ANTIMICROBIAL ACTIVITY; BREAST CANCER; CANCER; CLINICAL TRIAL; CREUTZFELDT JAKOB DISEASE; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; ENDOMETRIOSIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; IONTOPHORESIS; MALARIA; MUCOSA INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPOROSIS; OVARY CANCER; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; RESPIRATORY TRACT INFECTION; REVIEW; TRANSDERMAL PATCH; VACCINATION;

EID: 0242559062     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2003.10.005     Document Type: Review

References (82)

1. Wieland T. The history of peptide chemistry. Gutte B. Peptides: Synthesis, Structures and Applications. 1995;1-38 Academic Press.
2. Merrifield B. Solid phase peptide synthesis. Gutte B. Peptides: Synthesis, Structures and Applications. 1995;93-169 Academic Press.
3. Lowman H.B. Phage display of peptide libraries on protein scaffolds. Methods Mol. Biol. 87:1998;249-264.
4. Skelton N.J., et al. Structure-function analysis of a phage display-derived peptide that binds to insulin-like growth factor binding protein 1. Biochemistry. 40:2001;8487-8498.
5. Nakamura G.R., et al. Stable 'zeta' peptides that act as potent antagonists of the high-affinity IgE receptor. Proc. Natl. Acad. Sci. U.S.A. 99:2002;1303-1308.
6. Nakamura G.R., et al. A novel family of hairpin peptides that inhibit IgE activity by binding to the high-affinity IgE receptor. Biochemistry. 40:2001;9828-9835.
7. Cochran A.G., et al. Tryptophan zippers: stable, monomeric β-hairpins. Proc. Natl. Acad. Sci. U.S.A. 98:2001;5578-5583.
8. Boerman O.C., et al. Radio-labeled receptor-binding peptides: a new class of radiopharmaceuticals. Semin. Nucl. Med. 30:2000;195-208.
9. Shockley T.R., et al. Penetration of tumor tissue by antibodies and other immunoproteins. Ann. N. Y. Acad. Sci. 618:1991;367-382.
10. Dvorak H.F., et al. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells. 3:1991;77-85.
11. Luhrs P., et al. Induction of specific immune responses by polycation-based vaccines. J. Immunol. 169:2002;5217-5226.
12. Curnis F., et al. Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol. 18:2000;1185-1190.
13. Arap W., et al. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 279:1998;377-380.
14. Arap W., et al. Chemotherapy targeted to tumor vasculature. Curr. Opin. Oncol. 10:1998;560-565.
15. Koivunen E., et al. Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol. 17:1999;768-774.
16. Pasqualini R., Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature. 380:1996;364-366.
17. Zwaveling S., et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169:2002;350-358.
18. Dutoit V., et al. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J. Clin. Invest. 110:2002;1813-1822.
19. Sahin U., et al. Serological identification of human tumor antigens. Curr. Opin. Immunol. 9:1997;709-716.
20. Sundaram R., et al. Synthetic peptides as cancer vaccines. Biopolymers. 66:2002;200-216.
21. Machiels J.P., et al. Peptide-based cancer vaccines. Semin. Oncol. 29:2002;494-502.
22. Tsuji M., et al. Progress toward a malaria vaccine: efficient induction of protective anti-malaria immunity. Biol. Chem. 382:2001;553-570.
23. Arap W., et al. Targeting the prostate for destruction through a vascular address. Proc. Natl. Acad. Sci. U. S. A. 99:2002;1527-1531.
24. Chang S.S., et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59:1999;3192-3198.
25. St Croix B., et al. Genes expressed in human tumor endothelium. Science. 289:2000;1197-1202.
26. Bacich D.J., et al. Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm. Genome. 12:2001;117-123.
27. Arap W., et al. Steps toward mapping the human vasculature by phage display. Nat. Med. 8:2002;121-127.
28. Ganz T., Lehrer R.I. Antimicrobial peptides of vertebrates. Curr. Opin. Immunol. 10:1998;41-44.
29. Javadpour M.M., et al. De novo antimicrobial peptides with low mammalian cell toxicity. J. Med. Chem. 39:1996;3107-3113.
30. Mosca D.A., et al. IB-367, a protegrin peptide with in vitro and in vivo activities against the microflora associated with oral mucositis. Antimicrob. Agents Chemother. 44:2000;1803-1808.
31. Ellerby H.M., et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 5:1999;1032-1038.
32. Permanne B., et al. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a β-sheet breaker peptide. FASEB J. 16:2002;860-862.
33. Soto C., et al. Inhibition of Alzheimer's amyloidosis by peptides that prevent β-sheet conformation. Biochem. Biophys. Res. Commun. 226:1996;672-680.
34. Soto C., et al. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat. Med. 4:1998;822-826.
35. Soto C., et al. Reversion of prion protein conformational changes by synthetic β-sheet breaker peptides. Lancet. 355:2000;192-197.
36. Horiuchi M., et al. Inhibition of interactions and interconversions of prion protein isoforms by peptide fragments from the C-terminal folded domain. J. Biol. Chem. 276:2001;15489-15497.
37. Findeis M.A. Peptide inhibitors of β amyloid aggregation. Curr. Top. Med. Chem. 2:2002;417-423.
38. Ghosh A.K., et al. Targeting plasmodium ligands on mosquito salivary glands and midgut with a phage display peptide library. Proc. Natl. Acad. Sci. U. S. A. 98:2001;13278-13281.
39. Ito J., et al. Transgenic anopheline mosquitoes impaired in transmission of a malaria parasite. Nature. 417:2002;452-455.
40. Li F., et al. Phage-displayed peptides bind to the malarial protein apical membrane antigen-1 and inhibit the merozoite invasion of host erythrocytes. J. Biol. Chem. 277:2002;50303-50310.
41. Brown C.K., et al. A novel approach for the identification of unique tumor vasculature binding peptides using an E. coli peptide display library. Ann. Surg. Oncol. 7:2000;743-749.
42. Sidhu S.S., et al. Phage display for selection of novel binding peptides. Methods Enzymol. 328:2000;333-363.
43. Aina O.H., et al. Therapeutic cancer targeting peptides. Biopolymers. 66:2002;184-199.
44. Livnah O., et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 Å Science. 273:1996;464-471.
45. Lowman H.B., et al. Molecular mimics of insulin-like growth factor 1 (IGF-1) for inhibiting IGF-1: IGF-binding protein interactions. Biochemistry. 37:1998;8870-8878.
46. Haubner R., et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med. 42:2001;326-336.
47. Still J.G. Development of oral insulin: progress and current status. Diabetes Metab. Res. Rev. 18:(Suppl. 1):2002;S29-S37.
48. Kim T.H., et al. Pegylated recombinant human epidermal growth factor (rhEGF) for sustained release from biodegradable PLGA microspheres. Biomaterials. 23:2002;2311-2317.
49. Monkarsh S.P., et al. Positional isomers of monopegylated interferon α2a: isolation, characterization, and biological activity. Anal. Biochem. 247:1997;434-440.
50. Kjeldsen T., et al. Secretory expression of human albumin domains in Saccharomyces cerevisiae and their binding of myristic acid and an acylated insulin analogue. Protein Expr. Purif. 13:1998;163-169.
51. Koehler M.F., et al. Albumin affinity tags increase peptide half-life in vivo. Bioorg. Med. Chem. Lett. 12:2002;2883-2886.
52. Dennis M.S., et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. 277:2002;35035-35043.
53. Holmes D.L., et al. Site specific 1:1 opioid:albumin conjugate with in vitro activity and long in vivo duration. Bioconjug. Chem. 11:2000;439-444.
54. Hinds K.D., Kim S.W. Effects of PEG conjugation on insulin properties. Adv. Drug Deliv. Rev. 54:2002;505-530.
55. Lee K.C., et al. Isolation, characterization, and stability of positional isomers of mono-PEGylated salmon calcitonins. Pharm. Res. 16:1999;813-818.
56. Lee H., Park T.G. Preparation and characterization of mono-PEGylated epidermal growth factor: evaluation of in vitro biologic activity. Pharm. Res. 19:2002;845-851.
57. Peters T. Jr. Serum albumin. Adv. Protein Chem. 37:1985;161-245.
58. Syed S., et al. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood. 89:1997;3243-3252.
59. Henry S., et al. Microfabricated microneedles: a novel approach to transdermal drug delivery. J. Pharm. Sci. 87:1998;922-925.
60. Kanikkannan N., et al. Transdermal iontophoretic delivery of bovine insulin and monomeric human insulin analogue. J. Control. Release. 59:1999;99-105.
61. Kanikkannan N. Iontophoresis-based transdermal delivery systems. BioDrugs. 16:2002;339-347.
62. Nicoli S., et al. Physical and chemical enhancement of transdermal delivery of triptorelin. Pharm. Res. 18:2001;1634-1637.
63. Suzuki Y., et al. Prevention of bone loss in ovariectomized rats by pulsatile transdermal iontophoretic administration of human PTH(1-34). J. Pharm. Sci. 91:2002;350-361.
64. Mitragotri S., et al. Ultrasound-mediated transdermal protein delivery. Science. 269:1995;850-853.
65. Boucaud A., et al. Effect of sonication parameters on transdermal delivery of insulin to hairless rats. J. Control. Release. 81:2002;113-119.
66. Bot A.I., et al. Receptor-mediated targeting of spray-dried lipid particles coformulated with immunoglobulin and loaded with a prototype vaccine. Pharm. Res. 18:2001;971-979.
67. Duddu S.P., et al. Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere powder. Pharm. Res. 19:2002;689-695.
68. Hirst P.H., et al. In vivo lung deposition of hollow porous particles from a pressurized metered dose inhaler. Pharm. Res. 19:2002;258-264.
69. Cevc G., et al. Ultraflexible vesicles, transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochim. Biophys. Acta. 1368:1998;201-215.
70. Leone-Bay A., et al. Oral delivery of biologically active parathyroid hormone. Pharm. Res. 18:2001;964-970.
71. Modi P., et al. The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist System. Diabetes Metab. Res. Rev. 18:(Suppl. 1):2002;S38-S42.
72. Lowman A.M., et al. Oral delivery of insulin using pH-responsive complexation gels. J. Pharm. Sci. 88:1999;933-937.
73. Cefalu W.T. Evaluation of alternative strategies for optimizing glycemia: progress to date. Am. J. Med. 113:(Suppl. 6A):2002;S23-S35.
74. van't Hof W., et al. Antimicrobial peptides: properties and applicability. Biol. Chem. 382:2001;597-619.
75. Guo J., et al. Transdermal delivery of insulin in mice by using lecithin vesicles as a carrier. Drug Deliv. 7:2000;113-116.
76. Guo J., et al. Lecithin vesicular carriers for transdermal delivery of cyclosporin A. Int. J. Pharm. 194:2000;201-207.
77. Smith G.D., et al. The structure of T6 human insulin at 1.0 Å resolution. Acta Crystallogr. D Biol. Crystallogr. 59:2003;474-482.
78. Vajdos F.F., et al. Crystal structure of human insulin-like growth factor-1: detergent binding inhibits binding protein interactions. Biochemistry. 40:2001;11022-11029.
79. Trabi M., et al. Three-dimensional structure of RTD-1, a cyclic antimicrobial defensin from Rhesus macaque leukocytes. Biochemistry. 40:2001;4211-4221.
80. Neidigh J.W., et al. Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states. Biochemistry. 40:2001;13188-13200.
81. Deshayes K., et al. Rapid identification of small binding motifs with high-throughput phage display: discovery of peptidic antagonists of IGF-1 function. Chem. Biol. 9:2002;495-505.
82. Eigenbrot C., et al. The factor VII zymogen structure reveals reregistration of β-strands during activation. Structure (Camb.). 9:2001;627-636.